04/08/2024
5:44 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/03/2024
4:23 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/03/2024
4:23 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
7:30 AM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/12/2024
7:34 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
|
03/12/2024
7:40 AM | Inozyme Pharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/12/2024
7:32 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2024
6:11 PM | Inozyme Pharma (Subject)
Sofinnova Venture Partners X, L.P. (Filed by)
| Form SC 13D/A | |
02/14/2024
7:34 PM | Inozyme Pharma (Subject)
Venrock Healthcare Capital Partners II, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
5:08 PM | Inozyme Pharma (Subject)
New Enterprise Associates 15, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
12:40 PM | Inozyme Pharma (Subject)
SAMLYN CAPITAL, LLC (Filed by)
| Form SC 13G | |
02/14/2024
10:54 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G | |
02/14/2024
7:48 AM | Deep Track Capital, LP (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
02/12/2024
8:06 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
02/07/2024
6:46 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
02/05/2024
8:12 AM | Inozyme Pharma (Subject)
SPHERA FUNDS MANAGEMENT LTD. (Filed by)
| Form SC 13G/A | |
11/15/2023
11:15 PM | Inozyme Pharma (Filer)
| Form EFFECT | |
11/07/2023
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/07/2023
7:34 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
09/26/2023
3:12 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2023
7:37 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2023
8:03 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/07/2023
8:58 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
08/03/2023
7:01 PM | Hopfner Robert Lorne (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/03/2023
7:13 PM | Inozyme Pharma (Issuer)
Pivotal bioVenture Partners Fund I G.P., L.P. (Reporting)
Pivotal bioVenture Partners Fund I U.G.P. Ltd (Reporting)
Pivotal bioVenture Partners Fund I, L.P. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/28/2023
4:17 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
07/28/2023
4:19 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/27/2023
4:28 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
06/27/2023
3:05 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/15/2023
3:16 PM | Inozyme Pharma (Issuer)
Mathers Edward T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2023
3:36 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/31/2023
3:17 PM | Inozyme Pharma (Subject)
MILLENNIUM MANAGEMENT LLC (Filed by)
| Form SC 13G | |
05/23/2023
3:48 PM | Inozyme Pharma (Subject)
Pivotal bioVenture Partners Fund I, L.P. (Filed by)
| Form SC 13D/A | |
05/09/2023
7:43 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/09/2023
7:35 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/03/2023
7:40 AM | Bolte Axel (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/27/2023
7:31 AM | Inozyme Pharma (Filer)
| Form DEF 14A | |
04/27/2023
7:36 AM | Inozyme Pharma (Filer)
| Form DEFA14A | |
04/27/2023
7:41 AM | Inozyme Pharma (Filer)
| Form ARS | |
SHOCKING Crypto Leak… (Ad) A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products.
If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE…
The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
 Claim your free seat by clicking here now. |
